The regulator backed the medicine after phase 3 data showed dramatic reductions in HAE attacks and sustained disease control ...

A 79-year-old man was admitted to a hospital in Guangzhou, China, with progressive dyspnea and edema. Echocardiography and ...

ORLANDO -- Long-term results from trials of new drugs for hereditary angioedema (HAE) continue to support efficacy and safety ...

The impact of hereditary angioedema on pediatric patients and their caregivers goes beyond the disease itself and can take a ...

Discover a study showing barzolvolimab rapidly improves chronic spontaneous urticaria symptoms, offering hope for patients ...

Investing.com -- Intellia Therapeutics Inc (NASDAQ:NTLA) stock soared 13.8% in premarket trading Monday after the gene editing company presented positive clinical data for its hereditary angioedema ...

ORLANDO -- An orally disintegrating tablet form of sebetralstat (Ekterly) for young children with hereditary angioedema (HAE) ...

Open-label prophylaxis data supporting the long-term safety profile and sustained benefits of deucrictibant, as well as clinical validation data ...

At 2 years, Black and white patients who received Lucentis for the treatment of diabetic macular edema achieved similar ...

Topline data for RAPIDe-3, a pivotal Phase 3 study of deucrictibant immediate-release capsule for the on-demand treatment of HAE attacks, ...

Read ahead to know the eye infections and conditions brought on by diabetes and get expert tips to protect your vision ...